

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated May 17, 2019 (the “**Prospectus**”) of Frontage Holdings Corporation (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to sell, acquire, purchase or subscribe for any securities.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute and is not an offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933 (the “**U.S. Securities Act**”) or any state securities laws of the United States and may not be offered or sold in the United States absent registration under the U.S. Securities Act or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offering of securities of the Company in the United States.



FRONTAGE HOLDINGS CORPORATION

方達控股公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1521)

STABILISING ACTIONS, END OF STABILISATION PERIOD AND LAPSE OF OVER-ALLOTMENT OPTION

**For identification purpose only*

STABILISING ACTIONS AND END OF STABILISATION PERIOD

The Company announces that the stabilisation period in connection with the Global Offering ended on June 21, 2019, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. The stabilising actions undertaken by Merrill Lynch (Asia Pacific) Limited through its affiliates, as the Stabilising Manager, or any person acting for it during the stabilisation period were:

- (1) over-allocations of an aggregate of 75,286,000 Shares in the International Offering, representing approximately 15% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option); and
- (2) successive purchases of an aggregate of 75,286,000 Shares in the price range of HK\$3.03 to HK\$3.20 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the market during the stabilisation period. The last purchase made by the Stabilising Manager on the market during the stabilisation period was on June 21, 2019 at the price of HK\$3.16 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%);

LAPSE OF OVER-ALLOTMENT OPTION

The Joint Global Coordinators did not exercise the Over-allotment Option during the stabilization period and the Over-allotment Option lapsed on June 21, 2019.

PUBLIC FLOAT

Immediately after the completion of the Global Offering, the Company will continue to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules.

By order of the Board
Frontage Holdings Corporation
Chairman
Dr. Zhihe Li

Hong Kong, June 23, 2019

As of the date of this announcement, the Board of Directors comprises Dr. Zhihe Li as executive Director; Mr. Jun Gao as non-executive Director; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive Directors.